With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...

[시사저널e=최다은 기자] 미국 식품의약국(FDA)이 노보 노디스크의 비만 치료제 ‘위고비(Wegovy, 세마글루타이드 2.4mg)’를 MASH(대사이상성 지방간염, 구 NASH) 치료제로 승인했다. 이는 GLP-1 계열 ...

Wegovy is now approved by the FDA to treat metabolic-associated steatohepatitis in adults with moderate-to-advanced fibrosis ...

The FDA clearance sets Novo’s medicine up a market battle with Madrigal Pharmaceuticals’ fast-selling Rezdiffra.

노보 노디스크(Novo Nordisk)의 비만 치료제 위고비(Wegovy)가 지난 15일 미국 식품의약국(FDA)으로부터 대사 기능 이상 관련 지방간염(Metabolic dysfunction-Associated ...

The U.S. Food and Drug Administration (FDA) has approved Novo Nordisk's popular weight-loss drug Wegovy to treat a serious ...

[헬스코리아뉴스 / 이충만] 한미약품이 기술이전한 대사이상 관련 지방간염(MASH) 신약 후보물질 ‘에피노페그듀타이드’(efinopegdutide, MK-6024)의 임상 데이터 발표가 본격적인 카운트다운에 돌입했다.본지 ...

Wegovy is now positioned as the first and only GLP-1 treatment.

On Friday, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Wegovy has become a ...

Novo Nordisk's Wegovy has received accelerated approval for use in patients with metabolic dysfunction-associated ...

The label expansion could help Novo Nordisk “help shift the momentum” for Wegovy, after a difficult start to 2025, according ...

Investing.com -- Madrigal Pharmaceuticals (NASDAQ: MDGL) stock declined 4% in pre-market trading Monday after the FDA ...